Role of AMH as Diagnostic Tool for Polycystic Ovarian Syndrome

Original Article
  • 28 Downloads

Abstract

Background

To evaluate role of AMH as a diagnostic tool for PCOS.

Methods

This was a prospective case–control study on women attending Gynae OPD of Dr RML Hospital, New Delhi, from 1 November 2015 to 31 March 2017. Study comprised of 45 women with PCOS, diagnosed using Rotterdam criteria and 45 women as controls. Clinical history included oligomenorrhea, hirsutism, examination included BMI, Ferriman–Gallwey score, investigations included blood for FSH, LH, estradiol, TSH, prolactin, total testosterone, AMH level and pelvic USG which was done for all women.

Results

Both PCOS cases and control were matched for age and BMI. Median AMH levels of 4.32 ng/ml in PCOS cases was almost twice that of 2.32 ng/ml in controls (p = 0.001). Maximum diagnostic potential of AMH alone for PCOS was at a cut-off of 3.44 ng/ml with sensitivity of 77.78% and specificity of 68.89%. AMH was used as an adjunct to existing Rotterdam criteria as the fourth parameter OA+HA+PCOM+AMH (any three out of four) yielded sensitivity of 80%. However, when PCOM in Rotterdam criteria was replaced by AMH, OA+HA+AMH (any two out of three) or OA/HA+AMH resulted in sensitivity of 86.67 and 71.11%, respectively.

Conclusion

AMH levels were significantly higher in PCOS than in controls. AMH as an independent marker could not effectively diagnose PCOS. However, AMH levels as an adjunct to existing Rotterdam criteria for diagnosis of PCOS had good diagnostic potential.

Keywords

PCOS AMH Rotterdam criteria Hyperandrogenism (HA) Oligomenorrhea (OA) Polycystic ovarian morphology (PCOM) 

Notes

Acknowledgement

We thank all the patients who consented to participate in this study.

Compliance with Ethical Standards

Conflict of interest

All the authors declare that they have no relevant conflict of interest.

Ethical Approval

The study was approved by Medical Ethical committee of PGIMER & DR RML Hospital, New Delhi.

Informed Consent

Informed consent was taken from all the patients who agreed to participate in the study.

References

  1. 1.
    Begawy A, El-Mazny A, Abou-Salem N, et al. Anti-Müllerian hormone in polycystic ovary syndrome and normo-ovulatory women: correlation with clinical, hormonal and ultrasonographic parameters. Middle East Fertil Soc J. 2010;15(4):253–8.CrossRefGoogle Scholar
  2. 2.
    Mahran A. The relationship between Anti-mullerian hormone and the clinical, biochemical and sonographic parameters in women with polycystic ovarian syndrome. Middle East Fertil Soc J. 2015;21(1):11–5.CrossRefGoogle Scholar
  3. 3.
    Ramanand S, Ghongane B, Ramanand J, et al. Clinical characteristics of polycystic ovary syndrome in Indian women. Indian J Endocrinol Metab. 2013;17(1):138–45.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Broekmans F, de Ziegler D, Howles C, et al. The antral follicle count: practical recommendations for better standardization. Fertil Steril. 2010;94(3):1044–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Duijkers I, Klipping C. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol. 2010;26(3):152–60.CrossRefPubMedGoogle Scholar
  6. 6.
    Johnstone E, Rosen M, Neril R, et al. The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95(11):4965–72.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kristensen S, Ramlau-Hansen C, Ernst E, et al. A very large proportion of young Danish women have polycystic ovaries: is a revision of the Rotterdam criteria needed? Hum Reprod. 2010;25(12):3117–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Streuli I, Fraisse T, Pillet C, et al. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90(2):395–400.CrossRefPubMedGoogle Scholar
  9. 9.
    Sahmay S, Atakul N, Aydogan B, et al. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome. Acta Obstetriciaet Gynecologica Scandinavica. 2013;92(12):1369–74.CrossRefGoogle Scholar
  10. 10.
    Woo H, Kim K, Rhee E, et al. Differences of the association of anti-Mullerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome. Endocr J. 2012;59(9):781–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Iliodromiti S, Kelsey T, Anderson R, et al. Can Anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013;98(8):3332–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Köninger A, Koch L, Edimiris P, et al. Anti-Mullerian hormone: an indicator for the severity of polycystic ovarian syndrome. Arch Gynecol Obstet. 2014;290(5):1023–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Wiweko B, Maidarti M, Priangga M, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet. 2014;31(10):1311–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013;28(4):1077–83.CrossRefPubMedGoogle Scholar
  15. 15.
    Ramezani Tehrani F, Solaymani-Dodaran M, Hedayati M, et al. Is polycystic ovary syndrome an exception for reproductive aging? Hum Reprod. 2010;25(7):1775–81.CrossRefGoogle Scholar
  16. 16.
    Villarroel C, Merino P, Lopez P, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone. Hum Reprod. 2011;26(10):2861–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Lin Y, Chiu W, Wu C, et al. Antimüllerian hormone and polycystic ovary syndrome. Fertil Steril. 2011;96:230–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Tal R, Seifer D, Khanimov M, et al. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Am J Obstet Gynecol. 2014;211(1):59.e1–8.CrossRefGoogle Scholar
  19. 19.
    Cassar S, Teede H, Moran L, et al. Polycystic Ovary Syndrome and Anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotropins. Clin Endocrinol. 2014;81(6):899–906.CrossRefGoogle Scholar
  20. 20.
    Sopher A, Grigoriev G, Laura D, et al. Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. J Pediatr Endocrinol Metab. 2014;27:1175–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Tayrab E, Ali M, Modawe G, et al. Serum Anti-Müllerian hormone as laboratory predictor in infertile women with and without polycystic ovary syndrome. Am J Res Com. 2014;2(3):61–6.Google Scholar
  22. 22.
    Saikumar P, KalaiSelvi V, Prabhu K, et al. Anti Mullerian hormone: a potential marker for recruited non growing follicle of ovarian pool in women with polycystic ovarian syndrome. J Clin Diagn Res. 2013;7(9):1866–9.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Chao K, Ho C, Shyong W, et al. Anti-Mullerian hormone serum level as a predictive marker of ovarian function in Taiwanese women. J Chin Med Assoc. 2012;75(2):70–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Li Y, Ma Y, Chen X, et al. Different diagnostic power of anti-Mullerian hormone in evaluating women with polycystic ovaries with and without hyperandrogenism. J Assist Reprod Genet. 2012;29(10):1147–51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cengiz H, Ekin M, Dagdeviren H, et al. Comparison of serum anti-Müllerian hormone levels in normal weight and overweight–obese adolescent patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2014;180:46–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Hart R, Doherty D, Norman R, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Sahmay S, Aydin Y, Oncul M, et al. Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014;31(2):213–20.CrossRefPubMedGoogle Scholar
  29. 29.
    Eilertsen T, Vanky E, Carlsen S. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: Can morphologic description be replaced? Hum Reprod. 2012;27(8):2494–502.CrossRefPubMedGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2017

Authors and Affiliations

  1. 1.Department of Obstetric and GynecologyPGIMER and Dr RML HospitalNew DelhiIndia
  2. 2.New DelhiIndia
  3. 3.DwarkaIndia
  4. 4.NoidaIndia

Personalised recommendations